The FDA has published the background documents for tomorrow's Pharmacy Compounding Advisory Committee meeting, and they are worth reading before anyone tells you what the panel "decided." The agency posted seven scientific briefing documents, one for each substance under review, plus an introduction. [1]
The headline is consistent. FDA staff propose not adding BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax or Epitalon to the 503A Bulk Drug Substances List, the list a licensed pharmacy needs a substance on before it can compound that substance under a prescription. Across the documents, the agency's reasoning is similar from one peptide to the next: the substances are not well characterized, there is little or no human evidence of effectiveness for the proposed routes of use, and the human safety data is insufficient, including immunogenicity risks that have not been fully assessed. [2]
A detail that gets lost in social media summaries: the FDA reviewed narrow, specific uses, not the broad wellness claims that make these peptides popular. For BPC-157 the evaluated use is ulcerative colitis. For TB-500 it is wound healing, for MOTS-c obesity and osteoporosis, for Semax cerebral ischemia and migraine. [1] None of that is the same as the tendon, gut or longevity marketing you see online, and none of these peptides has been evaluated by the FDA for those wellness uses.
Two things this is not. It is not a vote, and it is not final. The committee still meets July 23 and 24 and makes its own recommendation, which is advisory and non-binding. Even a "yes" would only start formal FDA rulemaking, not change access on its own. And the public comment docket, FDA-2025-N-6895, closes today, July 22. [3]
Here is where we stand, and we say it plainly because we disclose our interest: Peppies is an independent, for-profit venture that would benefit only from a future legal, tested market, and we argue that a regulated pathway is safer for consumers than the unregulated grey market that fills the gap today. That is our position, not a neutral fact. The FDA's caution on thin human data is exactly the caution the grey market skips. Reporters and others have flagged the same evidence gap between the marketing and the clinical record. [4] We will publish a plain-English readout once the panel actually votes.
Sources
- FDA, July 23-24, 2026 PCAC meeting notice and event materials (briefing documents)
- FDA Briefing Document for BPC-157-Related Bulk Drug Substances (PDF)
- Regulations.gov, docket FDA-2025-N-6895
- Forbes, "FDA's Review Of Peptides Signals A Growing Public Health Challenge" (July 21, 2026)
The vote comes next. When the panel recommends and the FDA opens the comment window that carries legal weight, we'll tell you. Get notified →